AB-Biotics is a spanish biotech company focused on research, development, protection and distribution of biotechnological solutions, which make a contribution to improving the health and wellbeing of people.
It offers the pharmaceutical and food industries the comprehensive management of research projects.
It develops probiotics and other nutraceuticals for the pharmaceutical and food sectors. Among them AB-FORTIS (cognitive development of children) AB-LIFE (improvement of cardiovascular health) and AB-I3.1 (a probiotic for IBD/IBS)
It develops genetic analyses for conducting pharmacogenetic studies. One of them is Neurofarmagen, already in the market. It is a DNA chip that enables the assessment of the patient’s predisposition to respond to the drugs most widely used in treating depression, schizophrenia, bipolar disorders or epilepsy.